INDIANAPOLIS A clinical trial led by an Indiana University School of Medicine researcher found that weekly doses of semaglutide a medication typically prescribed to Type 2 diabetes patients improved blood sugar levels and weight loss for adult Type 1 diabetes patients who use automated insulin delivery systems and have a body mass index of 30 or higher
Tchang BG, Aras M, Kumar RB, et al
[14] [15] Current MHRA Guidance and Ongoing Safety Monitoring Retatrutide has no MHRA or EMA marketing authorisation
The MDS-UPDRS and CDR-SB cannot cleanly separate symptomatic relief from disease modification, and EVOKE showed the converse failure mode, biomarker movement without clinical benefit, so future trials should anchor on objective measures such as dopamine-transporter SPECT, neurofilament light chain, and tau, amyloid, and neuroinflammation PET
Anything outside that range isn't necessarily wrong, but it's worth examining dose, baseline body composition, and starting point